A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
J. Kremer, S. Cohen, Bethanie E. Wilkinson, C. Connell +8 more

